Nevin Manimala

Lancet Reg Health West Pac. 2026 May 25;71:101887. doi: 10.1016/j.lanwpc.2026.101887. eCollection 2026 Jun.

ABSTRACT

BACKGROUND: Lung cancer in Taiwan is never-smoking and adenocarcinoma (LUAD) predominant. This study evaluated national LUAD stage-shifts and their association with opportunistic, self-initiated low-dose computed tomography (LDCT) screening.

METHODS: A retrospective study was conducted using Taiwan Cancer Registry (TCR) data (2011-2023), and self-initiated LDCT screening records from five medical centers (2011-2021). Patients were classified as early-stage (stage I) and late-stage (stage II-IV). Outcomes included age-standardized incidence rate (ASIR), age-standardized incidence-based mortality (ASIBM), and average annual percentage change (AAPC) of national LUAD, and screening volume of self-initiated LDCT.

FINDINGS: Among 126,753 LUAD cases 71,159 (56.1%) were females and 87,830 (69.3%) never smoked. The opportunistic self-initiated LDCT screening revealed 70,803 individuals, most never smoked (83.7%) and were male (56.6%). ASIRs of stage 0 (AAPC, 49.6%; 95% confidence interval [CI], 43.3-71.0) and early-stage (AAPC, 13.0%; 95% CI, 12.3-13.7) increased significantly. Conversely, late-stage ASIRs declined in selected subgroups, including never-smoking females aged <55 years (AAPC, -1.9%; 95% CI, -0.3 to -0.9) and in smoking patients aged ≥75 years (males AAPC, -2.3%; 95% CI, -3.1 to -1.5; females AAPC, -3.9%; 95% CI, -6.3 to -1.3). Rising LDCT screening volume descriptively paralleled this stage-shift in never-smoking females. ASIBM declined significantly over time, particularly in advanced-stage disease.

INTERPRETATION: The coexistence of increasing early-stage incidence, largely stable late-stage disease, and declining incidence-based mortality suggests a transition phase characterized by both detection expansion and emerging clinical benefit. The increase in self-initiated LDCT screenings paralleled the stage-shift among never-smoking females, and further research is needed to assess long-term outcomes and cost-effectiveness.

FUNDING: Health Promotion Administration, Ministry of Health and Welfare; the Ministry of Health and Welfare and Formatting the Risk Prediction Models for Never-Smoking Lung Cancer (FORMOSA).

PMID:42239973 | PMC:PMC13227239 | DOI:10.1016/j.lanwpc.2026.101887

Front Med (Lausanne). 2026 May 19;13:1825410. doi: 10.3389/fmed.2026.1825410. eCollection 2026.

ABSTRACT

OBJECTIVES: Alpha-thalassemia is caused by deletional and/or mutational genetic abnormalities. Limited information exists in Saudi Arabia about the genotype-phenotype correlation. We asked if certain changes in laboratory parameters can predict the underlying genetic subgroup.

METHODS: All patients diagnosed with genetically defined alpha-thalassemia at King Saud University Medical City between 2017 and 2024 were included. Data were collected retrospectively. We hypothesized that there is no difference between the mutation and deletion groups in terms of complete blood count, hemoglobin electrophoresis parameters, or ferritin. Mann-Whitney U and independent samples t-tests were used for between-group comparisons. Fisher’s exact or chi-square tests were used for categorical variables. Two-sided p-values of <0.05 were considered statistically significant. A descriptive summary was conducted for all the other variables.

RESULTS: A total of 378 patients were identified with alpha-thalassemia, of whom 276 had deletion, 64 had mutation, and 38 had both mutation and deletion. Of the 340 patients included in the final comparative analysis, the median age was 27 years, and 216 were female. Higher indirect bilirubin (12.3% versus 4%, p-value 0.013), mean red cell distribution width (RDW) (18.8 versus 17.1, p-value of 0.005), and heterozygous genotype status (71.9% versus 57.5%, p-value 0.036) were seen in the mutation group. Hemoglobin H (HbH) detectability was higher in the mutation group than in the deletion group (1.63 versus 0.02, p-value <0.001). These differences in RDW % and HbH detectability held true even after adjusting for sickle hemoglobin (HbS) level, with p-values of 0.006 and <0.001, respectively. No statistical difference was found between the two groups in ferritin level.

CONCLUSION: Alpha-thalassemia mutations create a distinct hematologic phenotype characterized by increased red cell size variability, indirect bilirubin, and HbH compared to deletions, supporting different pathophysiological mechanisms. These could serve as simple laboratory markers to help distinguish between alpha-thalassemia subtypes, supporting the hypothesis that mutations create a more severe hemolytic phenotype than deletions.

PMID:42239965 | PMC:PMC13226189 | DOI:10.3389/fmed.2026.1825410

Front Med (Lausanne). 2026 May 11;13:1829629. doi: 10.3389/fmed.2026.1829629. eCollection 2026.

ABSTRACT

Rosacea is a chronic inflammatory skin disorder characterized by persistent facial erythema. Its clinical assessment relies on the Clinician’s Erythema Assessment (CEA), a subjective scale prone to inter-observer variability. To address the need for diagnostic consistency, this study developed a multimodal artificial intelligence framework for objective CEA grading using standardized VISIA® imaging. We analyzed a retrospective cohort of 1,001 patients. To establish a robust reference standard, three expert dermatologists conducted a multi-step collective audit to reach a unanimous consensus for each case. The framework integrated handcrafted image-derived tabular features with deep learning representations. During training, spatial data augmentations and Focal Loss were implemented to address dataset imbalance and mitigate overfitting. Our results demonstrated that the multimodal fusion model achieved statistically significant improvements over the strong image-only baseline (McNemar’s $p=0.031$ ; DeLong’s $p=0.024$ ), yielding a Macro-AUC of 0.902 (95% CI: 0.862-0.937). Furthermore, to address the ordinal nature of the disease severity, the fusion model achieved a Quadratic Weighted Kappa (QWK) of 0.800 and an Intraclass Correlation Coefficient (ICC) of 0.801 (95% CI: 0.720-0.860), indicating excellent alignment with expert consensus. Error analysis revealed that over 95% of misclassifications in intermediate grades (CEA3) were restricted to adjacent categories, reflecting strong clinical safety. Interpretability analysis via layer-wise relevance propagation confirmed the model’s focus on clinically recognized erythema-prone regions. This study establishes a robust proof-of-concept tool that transforms rosacea assessment from subjective inspection into an objective digital measurement, offering significant translational potential for clinical trials and teledermatology.

PMID:42239947 | PMC:PMC13227112 | DOI:10.3389/fmed.2026.1829629

Front Med (Lausanne). 2026 May 19;13:1819360. doi: 10.3389/fmed.2026.1819360. eCollection 2026.

ABSTRACT

INTRODUCTION: Pediatric medical device development remains limited, particularly for rare and complex conditions such as cyanotic congenital heart disease (CCHD). Although advances in surgery and diagnostics have improved survival, continuous and non-invasive monitoring of metabolic and physiological deterioration is not available outside hospital settings. Wearable devices could address this gap, but their clinical adoption requires alignment with real-world needs, usability, and healthcare workflows. This study aimed to capture clinician perspectives to inform the early development of a wearable multiparametric biosensor for pediatric CCHD within the European OrphaDev4Kids project (EU4H-2023-PJ).

METHODS: A structured, web-based anonymous survey was distributed through EPTRI channels to reach pediatric cardiology experts across Europe, including members of the OrphaDev4Kids Clinical Expert Committee. The questionnaire addressed current monitoring practices in CCHD, unmet clinical needs, usability and compliance, data integration, training requirements, and data governance. Quantitative responses were analyzed using descriptive statistics, and qualitative feedback was descriptively reviewed.

RESULTS: Clinicians reported that current CCHD monitoring relies mainly on imaging and basic physiological parameters, with minimal assessment of metabolic markers and no availability of non-invasive metabolic monitoring. Infancy, both before and after heart surgery, was identified as the most critical phase for remote monitoring. Respondents strongly supported non-invasive, multiparametric wearable devices providing threshold-based alerts and longitudinal summaries rather than continuous data streams. Comfort, intuitive design, and minimal disruption to daily activities were key determinants of patient compliance, while integration with clinical workflows, training, and technical support were essential for adoption. Clinicians also emphasized the importance of secure, regulation-compliant data handling. Despite limited familiarity with advanced wearable devices, clear and consistent expectations regarding functionality and usability emerged.

CONCLUSION: This expert consultation identifies a clear unmet need and strong clinical support for the development of wearable, multiparametric biosensors tailored to pediatric patients with CCHD. The findings provide actionable guidance for device design and highlight the importance of combining technological innovation with human-centered design, workflow integration, and robust data governance to enable future clinical adoption.

PMID:42239944 | PMC:PMC13226199 | DOI:10.3389/fmed.2026.1819360

J Hand Microsurg. 2026 May 21;18(4):100475. doi: 10.1016/j.jham.2026.100475. eCollection 2026 Jul.

ABSTRACT

BACKGROUND: Pyogenic flexor tenosynovitis (PFT) is a common hand infection associated with significant morbidity. Management varies due to lack of evidence-based guidelines, typically involving surgery and antibiotics. We conducted a cohort study, comparing outcomes between different surgical methods to see if one is optimal.

METHODS: Retrospective data collection of patients who underwent surgery for PFT in a single tertiary plastic surgery unit between 21 August 2013 and 4 October 2023 was undertaken. Demographics, injury mechanism, operative details and antibiotic use were recorded. Cases involving cellulitis or osteomyelitis were excluded. Outcomes included length of stay, length of follow-up and post-operative complications. Multivariable regression analyses were performed, adjusting for age, diabetes and smoking status.

RESULTS: A total of 174 patients (mean age 47.2 years [SD 18.7]) were included. PFT most commonly resulted from animal bites (23.7% of cases). There was wide variation in antibiotic prescribing practice. Open surgery was performed in 121 cases, whilst 53 underwent minimally invasive procedures. No statistically significant differences in outcomes were observed between techniques in unadjusted or adjusted analyses. Diabetes was associated with an increased likelihood of requiring further procedures on multivariable analysis.

CONCLUSION: There is no evidence of differing outcomes for open or minimally invasive techniques. Diabetes may be associated with a requirement for further procedures. However, these results should be interpreted in the context of the retrospective design, missing data and potential for confounding by indication. Standardised, evidence-based management guidelines are required, with prospective multi-centre studies needed to better define optimal treatment strategies.

PMID:42239939 | PMC:PMC13227196 | DOI:10.1016/j.jham.2026.100475

Med Devices (Auckl). 2026 May 29;19:595863. doi: 10.2147/MDER.S595863. eCollection 2026.

ABSTRACT

PURPOSE: Uncontrolled bleeding remains a major surgical challenge, increasing morbidity, operative time, and costs, highlighting the need for effective adjunctive hemostats. Veriset is a synthetic, absorbable patch that promotes clotting and provides mechanical hemostasis. While early studies show efficacy, real-world evidence across diverse settings is needed. This post-market, multicenter study evaluated the safety and effectiveness of Veriset in various surgical procedures.

METHODS: This observational, single-arm, prospective study was nested within Medtronic’s product surveillance registry. Sites were selected for procedural diversity (cardiovascular, soft-tissue, solid-organ), high Veriset use, and clinical study experience. Patients treated with Veriset as part of usual care were followed for 30 days post-procedure to monitor adverse events (AEs). The primary safety and effectiveness endpoints were device-related AEs within 30 days and hemostasis within 5 minutes, respectively. Secondary outcomes included time to hemostasis, length of hospital stay, and bleeding-site severity. Results were summarized using descriptive statistics and exact (Clopper-Pearson) confidence intervals.

RESULTS: Veriset was used on-label in 100 patients in cardiovascular (56), soft-tissue (18), solid-organ (18), and other (8) procedures. Most were performed via open surgery (90.0%), with 34% involving anastomoses. Median blood loss was 600 mL (interquartile range 200-1500), with transfusions in 24 patients. Of the 120 bleeding sites treated, pre-Veriset methods included sutures (55.8%, 67/120) and pressure (29.2%, 35/120). Bleeding was mostly mild/moderate (82.5%, 99/120). Device-related AEs occurred in 1 patient, with no deaths. Hemostasis within 5 minutes was achieved at 91.7% (110/120) of sites and in 96.0% (96/100) of patients. Median time to hemostasis was 2.0 minutes; median hospital stay was 7 days.

CONCLUSION: This study provides real-world evidence that Veriset is safe and suggests that it may be an efficacious and rapid adjunct for surgical hemostasis, including in high-risk cardiovascular and solid-organ procedures, supporting and extending prior trial data for routine clinical use.

CLINICALTRIALSGOV IDENTIFIER: NCT01524276, Dec 24, 2025.

PMID:42239929 | PMC:PMC13228841 | DOI:10.2147/MDER.S595863

Saudi Med J. 2026 Feb;47(2):283-290. doi: 10.15537/1658-3175.1009. Epub 2026 Feb 7.

ABSTRACT

OBJECTIVE: To investigate the risk factors, clinical manifestations, and treatment outcomes in patients with Primary Bone Sarcomas (PBS).

METHODS: This retrospective study included all patients with PBS treated between June 2016 and December 2023 at King Abdulaziz Medical City, excluding patients with incomplete data, presence of other malignancies, diagnosis at autopsy, or unknown metastasis. Data were analyzed using SPSS software version 27. A p-value of less than 0.05 was considered statistically significant. Log Rank test was used for survival analysis.

RESULTS: The study included 127 patients. Common past medical history included diabetes (7%), hypertension (5.5%), and metastasis at presentation (15%). Joint pain (76%) and bone swelling (75%) were common clinical presentations. The median overall survival was 5 years, with a 42% mortality rate. The presence of diabetes, hypertension, high Charlson score, high histological grading, and metastasis were more common among patients with osteosarcoma than other types (p < 0.05). Significant predictors of mortality included older age (HR: 1.03, p = 0.009), metastasis at presentation (HR: 8.19, p = 0.042), and metastasis (HR: 2.92, p = 0.010). Male gender (HR: 0.47, p = 0.020) had a lower risk of mortality.

CONCLUSION: This study highlights the significant burden of PBS in Saudi Arabia. Key risk factors such as age and metastasis at diagnosis significantly impact survival, underscoring the necessity for improved surveillance and follow-up strategies. Further research is needed to develop effective, risk-stratified treatment to improve outcomes for patients.

PMID:42239909 | PMC:PMC13227453 | DOI:10.15537/1658-3175.1009

Front Oncol. 2026 May 19;16:1732883. doi: 10.3389/fonc.2026.1732883. eCollection 2026.

ABSTRACT

BACKGROUND: Colon cancer incidence is increasing globally, yet its spatial and temporal dynamics in Central Asia remain insufficiently studied. This study aimed to assess regional disparities and temporal trends of colon cancer incidence in Kazakhstan from 2005 to 2024 using geospatial and age-period-cohort analyses.

METHODS: A nationwide population-based study was conducted using data from the Unified Nationwide Electronic Health System of Kazakhstan. Crude incidence rates (CR) and age-standardized incidence rates (ASR) were calculated per 100,000 population using the WHO world standard population. Spatial patterns were assessed based on the administrative division of 2005, and clustering was evaluated using the Getis-Ord Gi* statistic. Temporal trends were analyzed using Joinpoint regression and Age-Period-Cohort analysis modeling, including estimation of net drift, local drift, and period and cohort rate ratios.

RESULTS: The national CR was 9.64 per 100,000, and the ASR was 9.44 per 100,000. A persistent north-south gradient was observed, with higher incidence in northern and central regions (Pavlodar, Kostanay, Karaganda, North Kazakhstan, Astana) and lower rates in southern regions. Spatial clustering analysis identified significant hotspots in northern regions and coldspots in the south. Age-Period-Cohort analysis demonstrated a strong age effect across all models. The net drift was +0.57% per year (95% CI 0.23-0.91; p=0.001), with the highest increases observed in older age groups (65-84 years). Period and cohort effects were also significant, indicating the influence of demographic aging, healthcare changes, and generational risk factors.

CONCLUSION: Colon cancer incidence in Kazakhstan is characterized by pronounced spatial disparities and is primarily driven by population aging. The combined geospatial and Age-Period-Cohort analysis approach provides a comprehensive framework for understanding disease dynamics and supports the development of targeted cancer control strategies.

PMID:42239894 | PMC:PMC13225997 | DOI:10.3389/fonc.2026.1732883

Front Oncol. 2026 May 19;16:1761654. doi: 10.3389/fonc.2026.1761654. eCollection 2026.

ABSTRACT

BACKGROUND: Chemoradiotherapy (CRT) is the standard treatment for squamous cell carcinoma of the anal canal (ACC), achieving excellent local control and sphincter preservation. However, many long-term survivors experience persistent bowel, urinary, sexual, and psycho social sequelae affecting quality of life (QoL). The PROACT study (Patient – Reported Outcomes in Anal Cancer Patients Treated with Intensity-Modulated Radiotherapy; NCT06364579) wants to explore the relationship between oncologic outcomes and patient-reported QoL in the era of modern radiotherapy.

METHODS: This single-institution ambispective study included patients with a diagnosis of ACC treated between 2011 and 2024 with intensity modulated radiotherapy (IMRT)-based CRT, followed-when indicated-by an image guided interventional radiotherapy (IRT) boost. Oncologic outcomes and toxicity were assessed using standard criteria. QoL was evaluated annually up to 5 years post-treatment using the EORTC QLQ-C30 and anal cancer-specific QLQ-ANL27 questionnaires. Statistical analyses explored associations between QoL domains and patient-, disease-, and treatment-related factors.

RESULTS: Median age was 62 years (range 34-83); 82.2% were female. Median follow-up was 51 months. Three- and five-year overall survival were both 97.5%. Disease-free survival was 88.2% and 84.5% at three and five years, respectively, while locoregional relapse-free survival was 92.8% and 89.0%. Colostomy-free survival showed identical rates at three and five years (97.3%). Late≥ G3 Gastrointestinal toxicity occurred in 6 patients (6.7%). Compared with the general population, both sexes reported significantly higher global QoL (males p = 0.002; females p = 0.001), while diarrhea was worst in women (p = 0.0008). Younger age (<70 years), female sex, and late GI toxicity correlated with poorer functional outcomes, particularly in bowel and sexual domains.

CONCLUSIONS: PROACT underscores that treatment success in anal cancer extends beyond cure, encompassing survivorship, functionality, and well-being. Integrating oncologic and patient-reported outcomes offers a comprehensive, patient-centered framework for optimizing long-term care.

PMID:42239889 | PMC:PMC13225979 | DOI:10.3389/fonc.2026.1761654

Front Oncol. 2026 May 19;16:1738955. doi: 10.3389/fonc.2026.1738955. eCollection 2026.

ABSTRACT

BACKGROUND/OBJECTIVES: Large Language Models (LLMs) are increasingly used in medicine for tasks ranging from patient communication to exam preparation. This study aimed to evaluate the feasibility of using a domain-specific, out-of-training-data radiation and cancer biology examination as a benchmarking framework for large language models, and to compare the accuracy and consistency of commonly used LLMs available at the time of data collection.

METHODS: GPT-3.5, GPT-4, and Llama-2 were queried with 335 multiple-choice questions (MCQs) from the 2023 American Society for Radiation Oncology (ASTRO) Radiation and Cancer Biology Exam Study Guide, excluding image-based items. Each model answered all questions five times over three months to evaluate consistency. Model responses were scored against the official answer key and analyzed using one-way ANOVA with Bonferroni correction to determine statistical differences in accuracy.

RESULTS: GPT-4 achieved the highest accuracy, correctly answering 81% of questions, significantly outperforming GPT-3.5 (62%) and Llama-2 (51%) (p < 0.001). All models performed worse on questions requiring calculations, though differences were not statistically significant. In terms of reliability, GPT-4 and Llama-2 provided consistent responses more frequently than GPT-3.5. Despite stable overall scores, all models exhibited variability in individual responses across repeated trials. GPT-4 produced the longest explanations, averaging 183 words per answer.

CONCLUSIONS: This study demonstrates the feasibility of using a domain-specific, out-of-training-data examination to benchmark large language model knowledge in radiation and cancer biology. While performance differences were observed among models, variability and limitations, particularly in calculation-based questions, highlight the importance of methodological benchmarking and cautious interpretation when considering medical educational applications.

PMID:42239883 | PMC:PMC13225992 | DOI:10.3389/fonc.2026.1738955